Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer.

Zhenwei WangZhihong DaiBingwei WangYuren GaoXiang GaoLiang WangSihai ZhouLiqin YangXiaofu QiuZhiyu Liu

Published in: OncoTargets and therapy (2021)

The combination of the c-MET inhibitor PHA665752 and the PARP inhibitor olaparib may be a promising therapeutic strategy in patients with prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
tyrosine kinase
dna damage
oxidative stress